Navigation Links
Applied BioMath, LLC and CytomX Therapeutics, Inc. announce a collaboration to develop a Quantitative Systems Pharmacology Probody platform model for use in lmmuno-Oncology
Date:2/1/2017

LINCOLN, Mass., Jan. 31, 2017 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug development, today announced that it will collaborate with CytomX Therapeutics (www.cytomx.com) to develop a quantitative systems pharmacology (QSP) model of CytomX Therapeutics' Probody platform.

"We chose Applied BioMath for this project because their past work with us has proven that they are the leader in applying QSP approaches in drug development. We look forward to this collaboration to help us maximize the efficiency of our probody platform for immuno-oncology. "

Michael Kavanaugh, MD, Chief Scientific Officer of CytomX Therapeutics

CytomX Therapeutics' novel Probody Platform allows the design of drugs that take advantage of unique conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody while reducing drug activity in healthy tissue.  Applied BioMath's QSP platform model will be systematically studied to better understand how avidity and target expression affect tissue targeting. This model will also be used to predict optimal drug properties and to help understand how to optimize probody efficiencies to maximize anti-tumor targeting while minimizing the normal tissue binding.

"The Probody platform from CytomX Therapeutics is exemplary of the novel approaches needed to transform drug development. We are thrilled to help maximize the efficiency of their innovations leveraging our own proprietary technologies. "

Dr. John Burke, PhD, Co-Founder, President, and CEO of Applied BioMath

About Applied BioMath

Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, helps biotechnology and pharmaceutical companies answer complex, critical Go/No-go decisions in R&D.  Applied BioMath leverages biology, proprietary mathematical modeling and analysis technology, high-performance computing, and decades of industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, and the best path forward.  Our involvement shortens project timelines, lowers cost, and increases the likelihood of a best-in-class drug.  We provide clarity to complex situations, answer otherwise unanswerable questions, and our approach, when validated in the clinic, is 10x more accurate than traditional methodologies.

Applied BioMath and the Applied BioMath logo are trademarks of Applied BioMath, LLC.

Press Contact:
Kristen Zannella
kristen.zannella@appliedbiomath.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/applied-biomath-llc-and-cytomx-therapeutics-inc-announce-a-collaboration-to-develop-a-quantitative-systems-pharmacology-probody-platform-model-for-use-in-lmmuno-oncology-300399748.html


'/>"/>
SOURCE Applied BioMath
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Applied BioMath, LLC presents work in immuno-oncology and antibody drug-conjugates at Keystone Symposium
2. Applied BioMath, LLC to present at Boston Area Group for Informatics and Modeling Meeting
3. Applied Biophysics Engages ibidi USA as Manufacturer’s Representative in the US and Canada
4. Pittcon Solicits Call for Nominations for 2017 Awards in Areas of Analytical Chemistry and Applied Spectroscopy
5. Applied BioPhysics Introduces pFlow Peristaltic Pump
6. Dr. Joseph Loscalzo, MD, PhD announced as newest member of the Applied BioMath Scientific Advisory Board
7. Applied BioMath, LLC. To Sponsor and Present at QSP Congress Boston 2015
8. Pittcon Recognizes Achievements in Analytical Chemistry and Applied Spectroscopy
9. Applied Silicone Launches Silicone Gel System with Dual Matrix Technology
10. Applied DNA Sciences to Host Conference Call Tuesday August 12, 2014
11. Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... ... has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and ... of osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular ...
(Date:10/10/2017)... Poway, California (PRWEB) , ... October 10, 2017 , ... ... afternoon speaking at his local San Diego Rotary Club. The event ... San Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... Phoenix, Arizona (PRWEB) , ... October 09, 2017 ... ... of Kindred, a four-tiered line of medical marijuana products targeting the needs of ... production and packaging of Kindred takes place in Phoenix, Arizona. , As operators ...
Breaking Biology Technology:
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at http://www.sec.gov . 2016 ...
(Date:4/11/2017)... Fla. , April 11, 2017 ... and secure authentication solutions, today announced that it ... Intelligence Advanced Research Projects Activity (IARPA) to develop ... Thor program. "Innovation has been a ... IARPA,s Thor program will allow us to innovate ...
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
Breaking Biology News(10 mins):